Regulatory Perspectives on Multiplicity in Adaptive Design Clinical Trials throughout a Drug Development Program

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.21, Iss.4, 2011-07, pp. : 846-859

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adaptive Approaches in Clinical Drug Development: Opportunities and Challenges in Design and Implementation

By Krams Michael

Pharmaceutical Medicine, Vol. 23, Iss. 3, 2009-06 ,pp. : 139-148

Adis International

Access to resources Recommend Favorite

An Adaptive Optimal Design for the Emax Model and Its Application in Clinical Trials

By Leonov Sergei

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 2, 2009-03 ,pp. : 360-385

Taylor & Francis Ltd

Access to resources Recommend Favorite

Sample Size Re-Estimation for Adaptive Sequential Design in Clinical Trials

By Gao Ping

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 6, 2008-11 ,pp. : 1184-1196

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Guest Editorial - Statistical Issues in Adaptive Design Methods in Clinical Trials

By Dragalin Vladimir

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 6, 2007-11 ,pp. : 955-956

Taylor & Francis Ltd

Access to resources Recommend Favorite